TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026 annual meeting, being held April 18 - 22, 2026, in Chicago, Illinois. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below.

GlobeNewsWire • 3 hours ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (Nasdaq: TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progres.

Business Wire • Mar 2, 2026

TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line

TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.

Zacks Investment Research • Feb 27, 2026

TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion

TG Therapeutics remains a "Strong Buy," driven by robust BRIUMVI revenue growth and ambitious expansion initiatives. The company reported $594 million in 2025 U.S. BRIUMVI sales, a 90% YoY increase, and guides for $825–$850 million in 2026. Key catalysts include the phase 3 ENHANCE study (consolidated dosing) and a self-administered subcutaneous BRIUMVI, both targeting significant market segments.

Seeking Alpha • Feb 27, 2026

TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript

TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively

GlobeNewsWire • Feb 26, 2026

TG Therapeutics (TGTX) Misses Q4 Earnings Estimates

TG Therapeutics (TGTX) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.15 per share a year ago.

Zacks Investment Research • Feb 26, 2026

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET

GlobeNewsWire • Feb 23, 2026

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 23, 2026

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS

GlobeNewsWire • Feb 8, 2026